Exposure to biological therapies during conception and pregnancy: a systematic review
- 14 December 2017
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 178 (1) , 95-102
Abstract
Biological therapies are effective treatments for psoriasis and are often prescribed to women of child-bearing age. To evaluate the safety of biological therapy in conception and/or pregnancy. We performed a systematic review of PubMed, MEDLINE, Embase and Cochrane databases for multivariate-adjusted studies of women exposed to biologics relevant to the treatment of psoriasis during conception and/or pregnancy. We identified four population-based cohort studies involving 1300 women exposed to tumour necrosis factor (TNF)-α inhibitors (TNFi) 3 months prior to or during the first 3 months of pregnancy. These studies showed a trend towards drug-specific harm with TNFi exposure in women with different inflammatory diseases, with an increased risk of congenital malformations [three studies; odds ratio (OR) range 1·32–1·64] and preterm birth (one study; OR 1·69, 95% confidence interval 1·10–2·60). This trend did not reach statistical significance in all studies; study heterogeneity, variation across comparator cohorts, inadequate adjustment for important confounding variables such as co-therapy, and an absence of a common constellation of malformations means there is uncertainty about the causal role of TNFi. No studies specifically addressed the effect of TNFi exposure in psoriasis during conception and/or pregnancy, or of interleukin (IL)-17 and IL-12/23 antagonists in any indication. When counselling women these findings must be balanced against the potential impact of untreated severe psoriasis on conception and/or pregnancy and maternal wellbeing; ongoing pharmacovigilance via registries remains essential to address this evidence gap.Keywords
Funding Information
- National Institute for Health Research
- National Institute on Handicapped Research
- Guy's and St Thomas' NHS Foundation Trust
- King's College London
This publication has 28 references indexed in Scilit:
- Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2013
- The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectivesBritish Journal of Dermatology, 2012
- Psoriasis and pregnancy outcomes: A nationwide population-based studyJournal of the American Academy of Dermatology, 2011
- Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence studyJournal of Internal Medicine, 2010
- Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeedingRheumatology, 2010
- Crohn's Disease Is a Risk Factor for Preterm BirthClinical Gastroenterology and Hepatology, 2010
- A Safety Assessment of Tumor Necrosis Factor Antagonists During Pregnancy: A Review of the Food and Drug Administration DatabaseThe Journal of Rheumatology, 2009
- Human Tumour Necrosis Factor: Physiological and Pathological Roles in Placenta and EndometriumPlacenta, 2009
- A meta-analysis on the influence of inflammatory bowel disease on pregnancyGut, 2006
- Evolution of Maternofetal Transport of Immunoglobulins During Human PregnancyAmerican Journal of Reproductive Immunology, 1996